Skip to main content
CTOS 2023 Main banner
Final Program


Schedule at a Glance
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back

Brian A. Van Tine, MD, PhD (he/him/his)

Professor of Medicine
Washington University School of Medicine
St. Louis, Missouri, United States

Brian Andrew Van Tine, M.D., Ph.D. is a Professor of Medicine and Professor of Pediatrics at Washington University in St Louis, Missouri. He is the Sarcoma Program Director, Director of the Phase 1 Program at Alvin J. Siteman Cancer Center and Co-Director of the Adolescence and Young Adult Program at the Alvin J. Siteman Cancer Center. Dr. Van Tine received his Bachelors of Science degree from the Departments of Chemistry and Biochemistry at The University of Arizona in 1995. Dr. Van Tine completed his M.D. and Ph.D. degrees at the University of Alabama at Birmingham in 2005. His thesis research focused on the role of Human Papilloma Virus (HPV) in the development of cervical cancer with Profs. Louis T. Chow and Thomas R. Broker. After completing his M.D., Ph.D., Dr. Van Tine came to Washington University in St. Louis where he did his Internal Medicine Residency and Medical Oncology Fellowship. He joined the laboratories of James J.D. Hsieh, M.D., Ph.D. and then Matthew Ellis, M.B., B.Chir., Ph.D., where he pursued his postdoctoral fellowship studying mouse genetics and genomics while clinically specializing in the treatment of sarcoma. His translational laboratory identified a common defect in sarcoma, the loss of ASS1 expression. His lab is working toward translating this finding to the clinic via clinical trials. They were the first to report argininosuccinate synthetase 1 is silenced in ~90% of sarcomas, which renders them susceptible to arginine deprivation therapy and glutaminase inhibitors because they cannot synthesize arginine. He has demonstrated that arginine starvation overcomes gemcitabine resistance in sarcoma, a concept being formally tested in a phase II prospective clinical trial. Finally, the laboratory was the first to identify the loss of malic enzyme 1 (ME1) in synovial sarcoma, a finding that has direct therapeutic consequences, as well as PHGDH dependency in osteosarcoma.

Disclosure information not submitted.

Presentation(s):